Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside
TheFly reported on January 7 that TD Cowen raised its price target on ILMN to $140 from $115 while maintaining a Hold rating.
Illumina Inc. (ILMN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 141,817 | $18,600,718 | +1% | 3.01% |
| 2. | Bayforest Capital Theodoros Tsagaris | 276 | $36,200 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.13 | 500 | $61,065.00 | 12,523 | 2025-11-03 | Filing | |
| $81.21 | 6,100 | $495,381.00 | 24,906 | 2025-05-12 | Filing | |
| $82.26 | 100 | $8,226.00 | 83,390 | 2025-05-13 | Filing | |
| $81.56 | 804 | $65,574.24 | 83,290 | 2025-05-13 | Filing | |
| $80.70 | 4,946 | $399,142.20 | 82,486 | 2025-05-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $136.09 | 323 | $43,957.07 | 17,887 | 2025-12-12 | Filing | |
| $129.27 | 549 | $70,969.23 | 10,952 | 2025-12-08 | Filing | |
| $112.84 | 315 | $35,544.60 | 8,314 | 2023-11-07 | Filing | |
| $167.04 | 500 | $83,520.00 | 45,524 | 2023-08-22 | Filing | |
| $190.08 | 500 | $95,040.00 | 46,022 | 2023-07-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,355,380 | $1,882,851,641 | 0.03% | |
| 2. | 1,626,776 | $213,367,940 | 0.18% | |
| 3. | 1,522,323 | $199,667,885 | 0.03% | |
| 4. | 1,254,595 | $164,552,680 | 0.1% | |
| 5. | 944,500 | $124,145,080 | 0.11% |
News See All
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Illumina (ILMN) Soars 23.4% on Earnings Beat
“Illumina team delivered Q325 results that exceeded the high-end of our guidance range for revenue and earnings, driven by revenue acceleration in clinical, our largest market segment,” said CEO Jacob...
Illumina (ILMN) Jumps 24.8% on Earnings Beat
Illumina rallied for a second day on Friday, climbing 24.78 percent to close at $123.54 apiece after beating its earnings guidance in the third quarter of the year and projecting a lower revenue decline...
Illumina, Inc. (NASDAQ:ILMN) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen. Welcome to the Third Quarter 2025 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Illumina (ILMN) Expands TruSight Oncology Test With New KRAS CDx Collaborations
Illumina Inc. (NASDAQ:ILMN) ranks among the top NASDAQ stocks with low P/E ratios. On September 23, Illumina Inc.
Top 9 NASDAQ Stocks with Low P/E Ratios
The August reading of the Personal Consumption Expenditures (PCE) index, which includes the Fed's preferred "core" PCE measure of inflation, found prices increasing as expected.
Brown Advisory Global Leaders Strategy Exited Illumina (ILMN) in Q2. Here’s Why
Brown Advisory, an investment management company, released its “Brown Advisory Global Leaders Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Does Illumina (ILMN) have an Attractive Risk-Reward Opportunity for Long-Term Investors?
Baron Funds, an investment management company, released its “Baron Global Advantage Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here.
Illumina, Inc. (NASDAQ:ILMN) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen. Welcome to the Second Quarter 2025 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Hedge Fund Resource Center Billionaire Hedge Funds
